OMass Therapeutics
Biotech / small-molecule drug discovery, Oxford
Oxford biotech using native mass spectrometry to drug membrane proteins and complexes. It raised $310m in its Series C in October 2026. It has 1 role open, 1 of them in the UK.
Not found on the Home Office register of licensed visa sponsors.
- 4 daystypical age of an open role
- 0roles open for more than 60 days
- 0roles taken down since we started tracking
- 0%of roles list a salary
Open roles
1 live today- Discovery DMPK Scientist (Senior Scientist II / Principal Scientist)
Oxford, Oxford, United Kingdom
Raised a Series C in October
Salary not listed4 days agoApply
Open roles over time
Hiring momentum
Roles per weekAdded (by posting date)Closed (removed from the board)In the news (hover for headline)
Open roles by function
Open roles by team
As the company labels themIn the news
All 8 stories- OtherThe Pharma Letter, 17 days agoOMass Therapeutics
- FundingEU-Startups, 17 days agoOxford spin-out OMass Therapeutics lands €275 million to bring novel small-molecule therapies closer to patients
- OtherInfotechLead, 17 days agoVC funding deals: Stand, Ramp, OMass Therapeutics, OrbiMed
- OtherBioWorld News, 18 days agoFinancing at Omass Therapeutics to support lead program
- OtherEndpoints News, 18 days agoOMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder
- OtherInvesting.com UK, 8 May 2026Nxera Pharma sues OMass Therapeutics over patent infringement By Investing.com